Physician profile
Joseph Lapinsky
NPI 1306371430
$4,068.93
in general payments reported to CMS, 2019-2025
21 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $540 · 2023: $1,151 · 2024: $1,326 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091 · Education: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,090.89 |
| Education | $438.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $482.12 | 2022-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $445.22 | 2023-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $431.36 | 2022-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $419.00 | 2022-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $334.33 | 2022-2025 | Acthar |
| Calliditas Therapeutics US INC. | $294.04 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $273.98 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $214.77 | 2022-2025 | |
| Horizon Therapeutics Plc | $200.68 | 2022-2023 | Krystexxa |
| Ardelyx, INC. | $200.63 | 2024-2025 | Ibsrela |
| Amgen INC. | $198.04 | 2022-2025 | Krystexxa |
| Vifor Pharma, INC. | $189.41 | 2022-2024 | Veltassa |
| Aurinia Pharma U.S., INC. | $93.15 | 2022-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $78.20 | 2023-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $57.40 | 2022-2023 | Jesduvroq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $40.62 | 2024 | Jardiance, Mounjaro, Zepbound |
| Akebia Therapeutics INC | $29.76 | 2024 | Vafseo, Auryxia |
| Mannkind Corporation | $23.53 | 2025 | |
| Scpharmaceuticals INC. | $23.53 | 2025 | |
| Fresenius USA Marketing, INC. | $19.91 | 2025 | Velphoro |
| Averitas Pharma INC. | $19.25 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lapinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.